Rekombinanter CD1a Antikörper (full length)

Produktnummer ABIN7877847

Der Kaninchen Monoklonal anti-CD1a Antikörper wird verwendet zum Nachweis von CD1a in Proben von Human. Er wurde validiert für IHC (p).

Kurzübersicht für Rekombinanter CD1a Antikörper (full length) (ABIN7877847)

Target: CD1a

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser CD1a Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: C1A-8111R

Produktdetails anti-CD1a Antikörper

Bindungsspezifität: full length

Verwendungszweck: CD1a Antibody

Aufreinigung: Protein A/G affinity

Immunogen: Recombinant full-length human CD1a protein was used as the immunogen for the CD1a antibody.

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the CD1a antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the CD1a antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu CD1a

Target: CD1a

Andere Bezeichnung: CD1a

Hintergrund: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

UniProt: P06126

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process